Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer. https://xitter.cf/t.co/Y6oKrAMjFn
Massachusetts, USA
Joined July 2013
- Tweets1.5K
- Following1.1K
- Followers2.8K
- Likes749
Agenus retweeted
Highlights from Big Questions during ESMO 2026
On October 24 in Madrid, OncoDaily brought together leading voices from across the oncology community for an open discussion on the decisions shaping cancer research, treatment, and patient access.
Chaired by Prof. Jean-Yves Blay, the session featured Dr. Julie Gralow, Martha Raymond, and Dr. Jennifer S. Buell, bringing perspectives from clinical leadership, cancer policy, patient advocacy, and the biopharmaceutical industry.
🤝 With perspectives spanning clinical practice, research, industry, and patient advocacy, the discussion highlighted the importance of collaboration and shared responsibility in advancing cancer care.
@jeanyvesblay @jrgralow @jbuell01
Agenus retweeted
Here at the @oncodaily event @myesmo with some major leaders from @asco (@jrgralow, CMO), @Agenus_Bio (@jbuell01) and more! Come join us at Cafe Ramon here just outside the conference center #ESMO26 (registration is still open!) oncodaily.com/big-questions-…
Agenus retweeted
Yes! It is great to see MiNK CEO Dr. Jennifer S. Buell recognized among @oncodaily 100 Influential Women in Oncology 2026!
Breaking barriers, advancing immunotherapy, and redefining what’s possible for patients.
#WomenInOncology #iNKT #MiNKTherapeutics
Continuing a special OncoDaily tradition - 𝟭𝟬𝟬 𝗜𝗻𝗳𝗹𝘂𝗲𝗻𝘁𝗶𝗮𝗹 𝗪𝗼𝗺𝗲𝗻 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 - we are proud to present the 8th part of our 2026 list, celebrating the next 10 remarkable women whose leadership and contributions are shaping the future of oncology
🪄Jennifer S. Buell,(@jbuell01) PhD is the President and CEO of MiNK Therapeutics (@MiNK_iNKT) and Chair of the Executive Council and a Director at @Agenus_Bio, bringing more than 27 years of experience in cancer drug development and biotechnology. Previously President and COO of Agenus, she helped transform the company from a single-product biotechnology business into a fully integrated organization with a broad immuno-oncology pipeline and multiple global partnerships. Today, she leads MiNK’s development of allogeneic invariant natural killer T-cell therapies, while continuing to shape Agenus’ strategy for next-generation cancer immunotherapies.
🔗oncodaily.com/100/100-influe…
#Oncology #OncoDaily100 #OncoDaily #Cancer #100InfluentialWomen #WomenInOncology
Agenus retweeted
Agenus - A Defining Moment for Cancer Immunotherapy During ESMO 2026
@Agenus_Bio
oncodaily.com/voices/agenus-…
Agenus retweeted
Jennifer S. Buell Highlights Armenia’s First Marketing Authorizations for Botensilimab and Balstilimab
@jbuell01 @Agenus_Bio
oncodaily.com/industry/jenni…
Agenus retweeted
News from @MiNK_iNKT :
Three catalysts in three weeks:
#AACR2026 (Apr 20) → Phase II refractory GEJ
#ASGCT2026 (May 11-15) → mechanism in cancer + lung dx
#ATS2026 (May 20) → expanding pulmonary benefit
$INKT #Biotech #Catalyst #Immunotherapy #Celltherapy #breathe
Agenus retweeted
At #AACR26, Dr. Sam Cytryn @MSKCancerCenter reports INKT+BOT/BAL and chemo in r/r GEJ:
- 20% survival beyond 3 years in r/r GEJ
- Immune activation across assays
- Activity in active liver mets
In refractory disease, durability defines impact. @MiNK_iNKT @Agenus_Bio @YJanjigianMD
Agenus retweeted
A glimpse of what’s ahead #MHSRS2026 👀🫁— Dr. @TereseH43662 will present first look from a randomized Ph2 of agenT-797 in pulmonary dx at an outstanding MHSRS meeting #MajGenClintonMurray @HHSGov #Ukraine @DeptofWar @MiNK_iNKT
🤖 Made with AI
MiNK Therapeutics will share early findings from the first patients dosed in its randomized Phase 2 study of agenT-797 for hypoxemic pneumonia/ARDS at #MHSRS2026.
📅 Aug. 6 | 11:30–11:45 a.m.
Session: Cellular Therapies for Trauma
#agenT797 #ARDS #CellTherapy
Agenus retweeted
A world first 🇦🇲 Armenia grants the first marketing authorizations for botensilimab + balstilimab in previously treated MSS metastatic colorectal cancer. Gratitude to the patients, families & investigators who made this possible. @Agenus_Bio #CRCSM #Immunotherapy
Armenia has granted the first marketing authorizations for BOT+BAL in adults with previously treated MSS mCRC without active liver metastases.
Read more: bit.ly/4y9S81U
Agenus retweeted
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 biopharmawatch.com/news/INKT…
Our Head of Corporate Development and Investor Relations, Zack Armen, will participate in Chardan’s 10th Annual Healthcare Conference: The Next 10 years of Disruptive Innovation. See details below and in our press release: bit.ly/4y9S81U
Armenia has granted the first marketing authorizations for BOT+BAL in adults with previously treated MSS mCRC without active liver metastases.
Read more: bit.ly/4y9S81U
We presented 3-year follow-up data from our Phase 1b study of BOT+BAL in recurrent ovarian cancer at @IGCSociety’s #IGCS2026. Estimated overall survival was 48% at 3 years, unchanged from the 2-year estimate, in a heavily pretreated population. Learn more: bit.ly/3KSL3Qw
We will present new BOT+BAL research in colorectal cancer at #SITC2026, including long-term survivor data in refractory MSS mCRC and translational research evaluating BOT+BAL with agenT-797. See our presentation details below and in our press release: bit.ly/3KSL3Qw
Agenus retweeted
What NEST taught us
Lesson 5: Feasibility
FOxTROT & groups outside of US have helped move neoadjuvant therapy forward, but not routinely used in US. Patients we saw had a surgery date that was rescheduled.
#NEST3 now open for accrual! @OncoAlert
aacrjournals.org/clincancerr…
Missed our September Stakeholder Webcast yesterday? 🎥Watch the replay: bit.ly/4yxBj1p
Hear updates on ROBBIN Phase 3 execution, BOT+BAL and the rationale for immunotherapy before surgery.
#Agenus #BOTBAL #ColorectalCancer
🤖 Made with AI
Join us today at 4:30 p.m. ET for our September webcast featuring physician perspectives on treating earlier-stage disease with Dr. Benjamin Schlechter MD
Register and watch here: bit.ly/4iVgEjp
$AGEN
Agenus will present three-year overall survival data from the recurrent ovarian cancer cohort of the Phase 1b C-800-01 study evaluating BOT+BAL at #IGCS2026.
Read the release: bit.ly/3KSL3Qw
#OvarianCancer #ImmunoOncology $AGEN